Nitin Sampat Kamble

Dr. Nitin Sampat Kamble

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2021 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
STShindu C. Thomas
Shindu C. Thomas
TMTushar Madaan
Tushar Madaan
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
NSNabil A. Siddiqui
Nabil A. Siddiqui
GPGiovanni M. Pauletti
Giovanni M. Pauletti
NKNalinikanth Kotagiri
Nalinikanth Kotagiri

8 May 2025 in Gut Microbes
Verified
Journal Article
Open access
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
STShindu Thomas
Shindu Thomas
TMTushar Madaan
Tushar Madaan
NENadia Ehsani
Nadia Ehsani
SSSaqib Sange
Saqib Sange
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
The emergence of new viral pathogens necessitates innovative antiviral therapies and vaccines. Traditional approaches, such as monoclonal antibodies and vaccines, are often hindered by resistance, limited effectiveness, and high costs. Here, we develop an engineered probiotic-based antiviral platform using Escherichia coli Nissle 1917 (EcN), capable of providing both mucosal and systemic immunity via oral administration. EcN was engineered to display anti-spike nanobodies or express the Spike-Receptor Binding Domain on its surface. Our findings reveal that EcN with nanobodies effectively inhibits the interaction between spike protein-expressing pseudoviruses and the ACE2 receptor. Furthermore, we observed the translocation of nanobodies to distant organs, facilitated by outer membrane vesicles (OMVs). The oral administration of EcN expressing spike proteins induced a robust immune response characterized by the production of both IgG and IgA, antibodies that blocked the pseudovirus-ACE2 interaction. While SARS-CoV-2 served as a model, this versatile probiotic platform holds potential for developing customizable biotherapeutics against a wide range of emerging pathogens such as influenza virus or respiratory syncytial virus (RSV) by engineering EcN to express viral surface protein or neutralizing nanobodies demonstrating its versatility as a next-generation mucosal vaccine strategy.

10 July 2024 in Bacteria
Verified
Journal Article
Open access
PDF file
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
SBSUROJIT BERA
SUROJIT BERA
SBSanjeevani Amit Bhedase
Sanjeevani Amit Bhedase
VGVinita Gaur
Vinita Gaur
DEBABRATA CHOWDHURYDEBABRATA CHOWDHURY
DEBABRATA CHOWDHURY
It is imperative to say that we are immersed in a sea of microorganisms due to their ubiquitous presence on the planet, from soil to water and air. Human bodies harbor a vast array of microorganisms from both the inside and out called the human microbiome. It is composed of single-celled organisms, including archaea, fungi, viruses, and bacteria, including bacteriophages, where bacteria are the biggest players, and this is collectively referred to as the human microbiome. These organisms have a symbiotic relationship with humans and impact human physiology where they colonize various sites on and in the human body, adapting to specific features of each niche. However, dysbiosis, or the deviation from normal microbial composition, is associated with adverse health effects, disrupted ecosystems, and eco-imbalance in nature. In this review, we delve into the comprehensive oversight of bacteria, their cosmopolitan presence, and their additional applications affecting human lives.

19 July 2018 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
AFA M Frey
A M Frey
KAK Ansbro
K Ansbro
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
TPT K Pham
T K Pham
GSG P Stafford
G P Stafford
Tannerella HOT-286 (phylotype BU063) is a recently identified novel filamentous Gram-negative anaerobic oral bacterium cultured for the first time recently in co-culture with Propionibacterium acnes. In contrast to the related periodontal disease-associated pathobiont Tannerella forsythia, it is considered a putative health-associated bacterium. In this paper, we identified that this organism could be grown in pure culture if N-acetyl muramic acid (NAM) was provided in the media, although surprisingly the genetic basis of this phenomenon is not likely to be due to a lack of NAM synthesis genes. During further microbiological investigations, we showed for the first time that T. HOT-286 possesses a prominent extracellular S-layer with a novel morphology putatively made up of two proteins modified with an unknown glycan. These data further our knowledge of this poorly understood organism and genus that is an important part of the oral and human microbiome.

18 January 2019 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
CGCharlotte A. Green
Charlotte A. Green
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
ECElizabeth K. Court
Elizabeth K. Court
OBOwain J. Bryant
Owain J. Bryant
MHMatthew G. Hicks
Matthew G. Hicks
GSGraham P. Stafford
Graham P. Stafford
Many valuable biopharmaceutical and biotechnological proteins have been produced in Escherichia coli, however these proteins are almost exclusively localised in the cytoplasm or periplasm. This presents challenges for purification, i.e. the removal of contaminating cellular constituents. One solution is secretion directly into the surrounding media, which we achieved via the ‘hijack’ of the flagellar type III secretion system (FT3SS). Ordinarily flagellar subunits are exported through the centre of the growing flagellum, before assembly at the tip. However, we exploit the fact that in the absence of certain flagellar components (e.g. cap proteins), monomeric flagellar proteins are secreted into the supernatant. We report the creation and iterative improvement of an E. coli strain, by means of a modified FT3SS and a modular plasmid system, for secretion of exemplar proteins. We show that removal of the flagellin and HAP proteins (FliC and FlgKL) resulted in an optimal prototype. We next developed a high-throughput enzymatic secretion assay based on cutinase. This indicated that removal of the flagellar motor proteins, motAB (to reduce metabolic burden) and protein degradation machinery, clpX (to boost FT3SS levels intracellularly), result in high capacity secretion. We also show that a secretion construct comprising the 5′UTR and first 47 amino acidsof FliC from E. coli (but no 3′UTR) achieved the highest levels of secretion. Upon combination, we show a 24-fold improvement in secretion of a heterologous (cutinase) enzyme over the original strain. This improved strain could export a range of pharmaceutically relevant heterologous proteins [hGH, TrxA, ScFv (CH2)], achieving secreted yields of up to 0.29 mg L−1, in low cell density culture. We have engineered an E. coli which secretes a range of recombinant proteins, through the FT3SS, to the extracellular media. With further developments, including cell culture process strategies, we envision further improvement to the secreted titre of recombinant protein, with the potential application for protein production for biotechnological purposes.

22 March 2023 in Advanced Healthcare Materials
Verified
Journal Article
Open access
NSNabil A. Siddiqui
Nabil A. Siddiqui
AVAlec J. Ventrola
Alec J. Ventrola
AHAlexandra R. Hartman
Alexandra R. Hartman
TKTohonne Konare
Tohonne Konare
Nitin Sampat KambleNitin Sampat Kamble
Nitin Sampat Kamble
NKNalinikanth Kotagiri
Nalinikanth Kotagiri
Targeted radionuclide therapy (TRT) is an emerging therapeutic modality for the treatment of various solid cancers. Current approaches rely on the presence of cancer‐specific epitopes and receptors against which a radiolabeled ligand is systemically administered to specifically deliver cytotoxic doses of α and β particles to tumors. In this proof‐of‐concept study, tumor‐colonizing Escherichia coli Nissle 1917 (EcN) is utilized to deliver a bacteria‐specific radiopharmaceutical to solid tumors in a cancer‐epitope independent manner. In this microbe‐based pretargeted approach, the siderophore‐mediated metal uptake pathway is leveraged to selectively concentrate copper radioisotopes, 64Cu and 67Cu, complexed to yersiniabactin (YbT) in the genetically modified bacteria. 64Cu‐YbT facilitates positron emission tomography (PET) imaging of the intratumoral bacteria, whereas 67Cu‐YbT delivers a cytotoxic dose to the surrounding cancer cells. PET imaging with 64Cu‐YbT reveals persistence and sustained growth of the bioengineered microbes in the tumor microenvironment. Survival studies with 67Cu‐YbT reveals significant attenuation of tumor growth and extends survival of both MC38 and 4T1 tumor‐bearing mice harboring the microbes. Tumor response to this pretargeted approach correlates with promising anti‐tumor immunity, with noticeable CD8+ T:Treg cell ratio. Their strategy offers a pathway to target and ablate multiple solid tumors independent of their epitope and receptor phenotype.